#BEGIN_DRUGCARD DB01755

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C16H26N8O6S

# Chemical_IUPAC_Name:
(2S,3R)-2-amino-N-({[(2S,3R,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl}sulfamoyl)-3-methylpentanamide

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
N-[Isoleucinyl]-N'-[Adenosyl]-Diaminosufone

# HET_ID:
ILA

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C16H26N8O6S/c1-3-7(2)9(17)15(27)23-31(28,29)22-4-8-11(25)12(26)16(30-8)24-6-21-10-13(18)19-5-20-14(10)24/h5-9,11-12,16,22,25-26H,3-4,17H2,1-2H3,(H,23,27)(H2,18,19,20)/t7-,8+,9+,11+,12-,16-/m1/s1

# InChI_Key:
InChIKey=XVTRBLLRODNOJV-VRSYREPISA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
1755

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
458.493

# Molecular_Weight_Mono:
458.169601294

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
1JZQ

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.81

# Predicted_LogS:
-2.3

# Predicted_Water_Solubility:
2.26e+00 g/l

# Primary_Accession_No:
DB01755

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
46936207

# PubChem_Substance_ID:
46508937

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01859

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CC[C@@H](C)[C@H](N)C(=O)NS(=O)(=O)NC[C@@H]1O[C@H]([C@H](O)[C@H]1O)N1C=NC2=C1N=CN=C2N

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:28 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Cytoplasm

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
AP008226

# Drug_Target_1_GenBank_ID_Protein:
55772449

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
ileS

# Drug_Target_1_Gene_Sequence:
>3132 bp
ATGTTCAAGGAGGTCGGCGAGCCCAACTTTCCCAAGCTGGAAGAGGAGGTCTTGGCCTTC
TGGAAGCGGGAAAAGATCTTCCAAAAGAGCGTGGAAAACCGCAAAGGCGGTCCCCGCTAC
ACCGTCTACGAGGGCCCTCCCACCGCCAACGGCCTCCCCCACGTGGGCCACGCCCAGGCC
CGGAGCTACAAGGACCTCTTCCCCCGCTACAAGACCATGCGGGGCTACTACGCGCCCCGG
AGGGCAGGCTGGGACACCCACGGGCTTCCCGTGGAGCTGGAGGTGGAGAAGAAGCTCGGC
CTCAAGAGCAAGCGGGAGATTGAGGCCTACGGCATTGAGCGCTTCAACCAAGCCTGCCGC
GAGTCCGTCTTCACCTACGAGAAGGAGTGGGAGGCCTTTACCGAGCGCATCGCCTACTGG
GTGGACCTGGAGAACGCCTACGCCACCTTGGAACCCACCTATATTGAGAGCATCTGGTGG
AGCCTGAAGAACCTCTTTGACCGGGGCCTCCTCTACCGGGACCACAAGGTGGTGCCCTAC
TGCCCCCGCTGCGGCACCCCCCTCTCCTCCCACGAGGTCGCCCTGGGGTACAAGGAGATC
CAAGACCCCTCGGTCTACGTCCGCTTCCCCTTGAAGGAGCCGAAGAAGCTTGGCCTAGAG
AAGGCGAGCCTCCTCATCTGGACCACCACCCCCTGGACCCTGCCCGGGAACGTGGCCGCA
GCAGTCCACCCGGAGTACACCTACGCCGCCTTCCAGGTGGGAGACGAGGCCCTGATCCTG
GAGGAGGGGCTGGGGAGGAAGCTTTTGGGCGAGGGAACCCCGGTCCTCAAAACCTTCCCG
GGCAAGGCCCTGGAAGGCCTCCCCTACACCCCCCCCTACCCCCAGGCCTTGGAGAAGGGC
TACTTCGTGGTCCTCGCCGACTACGTGAGTCAAGAGGACGGGACGGGCATCGTCCACCAG
GCCCCCGCCTTCGGCGCCGAGGACCTGGAGACGGCGAGGGTCTACGGGCTTCCCCTCCTG
AAGACCGTGGACGAGGAGGGGAAGCTCCTCGTGGAGCCGTTTAAGGGCCTCTACTTCCGC
GAGGCCAACCGGGCGATCCTAAGGGACCTGAGGGGGCGGGGCCTCCTCTTCAAGGAGGAA
AGCTACCTCCACAGCTACCCCCACTGCTGGCGGTGCTCCACCCCCCTCATGTACTACGCC
ACGGAGAGCTGGTTCATCAAAAACACCCTCTTCAAGGACGAGCTCATCCGCAAGAACCAG
GAGATCCACTGGGTGCCCCCCCACATCAAGGAGGGCCGCTACGGGGAGTGGCTCAAGAAC
CTCGTGGACTGGGCCTTAAGCCGCAACCGCTACTGGGGGACACCCCTCCCCATCTGGGTC
TGCCAGGCGTGCGGCAAGGAGGAGGCCATCGGGAGCTTCCAGGAGCTCAAGGCGAGGGCC
ACGAAGCCCCTCCCCGAGCCCTTTGACCCCCACCGCCCCTACGTGGACCAGGTGGAGCTC
GCCTGTGCCTGCGGCGGGACCATGCGCCGCGTCCCCTACGTCATTGACGTCTGGTACGAC
TCCGGGGCCATGCCCTTCGCCTCCTTGCACTACCCCTTTGAGCACGAAGAGGTGTTCCGG
GAGAGCTTCCCCGCGGACTTCATCGCCGAGGGGATTGACCAGACCCGGGGCTGGTTCAAC
TCCCTCCACCAGCTCGGGGTGATGCTCTTCGGCTCCATCGCCTTCAAGAACGTGATCTGC
CACGGCCTCATCCTGGACGAAAAGGGGCAGAAGATGTCCAAGTCCAAGGGGAACGTGGTG
GACCCCTGGGACATCATCCGGGAGTTCGGGGCGGACGCCCTCAGGTGGTACATCTACGTC
TCCGCGCCTCCCGAGGCCGACCGGCGCTTCGGGCCCAACCTGGTTCGGGAAACGGTGCGG
GACTACTTCCTCACCCTCTGGAACGTCTACAGCTTCTTCGTGACCTACGCCAACCTGGAC
CGGCCCGACCTCAAGAACCCCCCTCCCCCCGAGAAGCGGCCCGAGATGGACCGCTGGCTC
CTCGCCCGCATGCAGGACCTCATCCAGAGGGTGACGGAGGCCCTCGAGGCCTACGACCCC
ACCACGAGCGCCCGCGCCCTGAGGGACTTCGTGGTGGAGGACCTCTCCCAGTGGTACGTC
CGCAGGAACCGGCGCCGCTTCTGGAAGAACGAGGACGCCCTGGACCGGGAGGCGGCCTAC
GCCACCCTCTACGAGGCCCTCGTCCTGGTGGCCACCCTCGCCGCCCCCTTCACCCCCTTC
CTCGCCGAGGTCCTGTGGCAGAACCTGGTGCGGAGCGTCCGGCCCGAGGCCAAGGAGAGC
GTCCACCTCGCCGACTGGCCCGAGGCCGACCCGGCCCTGGCCGACGAGGCCCTGGTGGCC
CAGATGCGGGCGGTGCTCAAGGTGGTGGACCTGGCCCGGGCGGCCCGGGCGAAAAGCGGG
GTCAAGACCCGCACCCCCCTTCCCCTCCTCCTCGTCACCGCCCCCACCGCCTTGGAGCGG
GAGGGGTTAAAGCGCTTCGCCCACGAGATCGCCGAGGAGCTCAACGTCAAGGAGGTCCGG
GTCCTGGAACCCGGGGAGGAGATCCTCTCCTACAGGGTCCTGCCCAACCTCAAGCTCCTG
GGGAGGAAGTACGGCAAGCTCGTCCCCAAAATCCGGGAGGCCCTGCAAAGGGAAAGGGAG
CGCGCCGCCGCCTTGGCGCTTAAGGGCGAGGCCATCCCCCTGGAGGTGGAGGGCGAGGCC
CTCACCCTCCTCCCGGAGGAGGTCCTCCTCGAGGCCGAGGCCCCCAAGGGCTACCAGGCC
CTGGAGAAGGACGGGTACGTGGCCGCCCTCAAGGTGGAGGTCACGGAAGCCCTCCGCATG
GAGGGCCTCGCCCGCGACCTCATCCGCCTCCTGCAGCAGGCCCGCAAAGACATGGGCCTC
AAGGTCTCGGACCGGATCCGGGTGGGCTACGAGGCGGAGGGCCCCTACCTCGAGGCCCTG
AAGCGGCACGGGCCCTGGATCGCCGAGGAGGTGCTGGCCACCGCCTTCGGGGAAGGCCTC
TTCGGCGGGTTTGAGGCCCGGGTGGAGGACGAGGAGGGCAAGGCGGTCTTCCACCTGGCC
CGGGCGGAGTGA

# Drug_Target_1_General_Function:
Translation, ribosomal structure and biogenesis

# Drug_Target_1_General_References:
9554847	Nureki O, Vassylyev DG, Tateno M, Shimada A, Nakama T, Fukai S, Konno M, Hendrickson TL, Schimmel P, Yokoyama S: Enzyme structure with two catalytic sites for double-sieve selection of substrate. Science. 1998 Apr 24;280(5363):578-82.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2509

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
119248

# Drug_Target_1_Name:
Isoleucyl-tRNA synthetase

# Drug_Target_1_Number_of_Residues:
1043

# Drug_Target_1_PDB_ID:
1JZS

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00133	tRNA-synt_1
PF08264	Anticodon_1

# Drug_Target_1_Protein_Sequence:
>Isoleucyl-tRNA synthetase
MFKEVGEPNFPKLEEEVLAFWKREKIFQKSVENRKGGPRYTVYEGPPTANGLPHVGHAQA
RSYKDLFPRYKTMRGYYAPRRAGWDTHGLPVELEVEKKLGLKSKREIEAYGIERFNQACR
ESVFTYEKEWEAFTERIAYWVDLENAYATLEPTYIESIWWSLKNLFDRGLLYRDHKVVPY
CPRCGTPLSSHEVALGYKEIQDPSVYVRFPLKEPKKLGLEKASLLIWTTTPWTLPGNVAA
AVHPEYTYAAFQVGDEALILEEGLGRKLLGEGTPVLKTFPGKALEGLPYTPPYPQALEKG
YFVVLADYVSQEDGTGIVHQAPAFGAEDLETARVYGLPLLKTVDEEGKLLVEPFKGLYFR
EANRAILRDLRGRGLLFKEESYLHSYPHCWRCSTPLMYYATESWFIKNTLFKDELIRKNQ
EIHWVPPHIKEGRYGEWLKNLVDWALSRNRYWGTPLPIWVCQACGKEEAIGSFQELKARA
TKPLPEPFDPHRPYVDQVELACACGGTMRRVPYVIDVWYDSGAMPFASLHYPFEHEEVFR
ESFPADFIAEGIDQTRGWFNSLHQLGVMLFGSIAFKNVICHGLILDEKGQKMSKSKGNVV
DPWDIIREFGADALRWYIYVSAPPEADRRFGPNLVRETVRDYFLTLWNVYSFFVTYANLD
RPDLKNPPPPEKRPEMDRWLLARMQDLIQRVTEALEAYDPTTSARALRDFVVEDLSQWYV
RRNRRRFWKNEDALDREAAYATLYEALVLVATLAAPFTPFLAEVLWQNLVRSVRPEAKES
VHLADWPEADPALADEALVAQMRAVLKVVDLARAARAKSGVKTRTPLPLLLVTAPTALER
EGLKRFAHEIAEELNVKEVRVLEPGEEILSYRVLPNLKLLGRKYGKLVPKIREALQRERE
RAAALALKGEAIPLEVEGEALTLLPEEVLLEAEAPKGYQALEKDGYVAALKVEVTEALRM
EGLARDLIRLLQQARKDMGLKVSDRIRVGYEAEGPYLEALKRHGPWIAEEVLATAFGEGL
FGGFEARVEDEEGKAVFHLARAE

# Drug_Target_1_Reaction:
ATP + L-isoleucine + tRNAIle = AMP + diphosphate + L-isoleucyl-tRNAIle

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Catalyzes the attachment of isoleucine to tRNA(Ile). As IleRS can inadvertently accommodate and process structurally similar amino acids such as valine, to avoid such errors it has two additional distinct tRNA(Ile)-dependent editing activities. One activity is designated as 'pretransfer' editing and involves the hydrolysis of activated Val-AMP. The other activity is designated 'posttransfer' editing and involves deacylation of mischarged Val-tRNA(Ile)

# Drug_Target_1_SwissProt_ID:
P56690

# Drug_Target_1_SwissProt_Name:
SYI_THET8

# Drug_Target_1_Synonyms:
EC 6.1.1.5
IleRS
Isoleucine--tRNA ligase

# Drug_Target_1_Theoretical_pI:
6.23

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01755
